Complementary Usage ofRhodiola crenulata(L.) in Chronic Obstructive Pulmonary Disease Patients: The Effects on Cytokines and T Cells
| Autor: | James Cheng-Chung Wei, Tsong-Ming Lu, Rosa Huang Liu, Chung-Hung Tsai, Wei-Yu Tsai, Tzu-Chin Wu, Shih-Pin Chen, Chi-Chiang Yang |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Pharmacology
COPD medicine.medical_specialty biology business.industry medicine.medical_treatment FOXP3 medicine.disease Placebo biology.organism_classification Gastroenterology respiratory tract diseases Pathogenesis Cytokine Internal medicine Immunology Rhodiola medicine IL-2 receptor business CD8 |
| Zdroj: | Phytotherapy Research. 29:518-525 |
| ISSN: | 0951-418X |
| DOI: | 10.1002/ptr.5259 |
| Popis: | Although chronic obstructive pulmonary disease (COPD) is an inflammatory disease predominantly involving T cells, no study of Rhodiola as an immunomodulator in COPD patients has been reported. In this study, COPD patients took Rhodiola crenulata 500 mg (n = 38) or placebo (starch/phosphate buffered saline) (n = 19) daily for 12 weeks and were compared with untreated, age-matched, and sex-matched non-COPD control subjects. Our results showed that serum levels of IL-2, IL-10, and IFN-γ in COPD patients before treatment are significantly higher than levels in non-COPD controls (p 0.05). The results suggested that Rhodiola treatment had beneficial antiinflammation effects, lower COPD assessment test score and decreased high-sensitivity C-reactive protein, on COPD patients (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text